NMI HoldingsNMIH
NMIH
About: NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
Employees: 230
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
214% more call options, than puts
Call options by funds: $937K | Put options by funds: $298K
33% more repeat investments, than reductions
Existing positions increased: 137 | Existing positions reduced: 103
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 40
1.75% less ownership
Funds ownership: 96.49% [Q3] → 94.74% (-1.75%) [Q4]
2% less funds holding
Funds holding: 330 [Q3] → 324 (-6) [Q4]
13% less capital invested
Capital invested by funds: $3.16B [Q3] → $2.76B (-$409M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$41
11%
upside
Avg. target
$42
13%
upside
High target
$43
16%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
Keefe, Bruyette & Woods Bose George 68% 1-year accuracy 28 / 41 met price target | 16%upside $43 | Outperform Upgraded | 24 Feb 2025 |
UBS Doug Harter 0 / 0 met price target | 11%upside $41 | Neutral Maintained | 19 Feb 2025 |
Barclays Terry Ma 52% 1-year accuracy 11 / 21 met price target | 11%upside $41 | Equal-Weight Downgraded | 6 Jan 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
2 hours ago
NMIH Stock Lags Industry, Trades at Discount: Time to Buy the Dip?
NMI Holdings is well-positioned for growth, with new primary insurance written, direct primary insurance in force and a better risk-based capital ratio.
Positive
Zacks Investment Research
4 weeks ago
NMIH Stock Trading at a Discount to Industry at 1.3X: Time to Hold?
NMI Holdings stock is poised to gain from higher new insurance written volume, a comprehensive reinsurance program, financial flexibility and prudent capital deployment.
Negative
Zacks Investment Research
1 month ago
NMI Holdings Q4 Earnings and Revenues Miss Estimates, Premiums Up Y/Y
NMIH's fourth-quarter results reflect higher premiums and net investment income but lower persistency.
Neutral
Seeking Alpha
1 month ago
NMI Holdings, Inc. (NMIH) Q4 2024 Earnings Call Transcript
NMI Holdings, Inc. (NASDAQ:NMIH ) Q4 2024 Earnings Conference Call February 6, 2025 5:00 PM ET Company Participants John Swenson - Vice President of Investor Relations, and Treasury Brad Shuster - Executive Chairman Adam Pollitzer - President and Chief Executive Officer Aurora Swithenbank - Chief Financial Officer Conference Call Participants Doug Harter - UBS Terry Ma - Barclays Capital Bose George - KBW Rick Shane - J.P. Morgan Mark Hughes - Truist Securities Mihir Bhatia - Bank of America Operator Good day, and welcome to the NMI Holdings, Inc. Fourth Quarter 2024 Earnings Conference Call.
Positive
Zacks Investment Research
1 month ago
NMI Holdings (NMIH) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for NMI Holdings (NMIH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Negative
Zacks Investment Research
1 month ago
NMI Holdings (NMIH) Lags Q4 Earnings and Revenue Estimates
NMI Holdings (NMIH) came out with quarterly earnings of $1.07 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.01 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
NMI Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results; Announces Additional $250 Million Share Repurchase Authorization
EMERYVILLE, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- NMI Holdings, Inc. (Nasdaq: NMIH) today reported net income of $86.2 million, or $1.07 per diluted share, for the fourth quarter ended December 31, 2024, which compares to $92.8 million, or $1.15 per diluted share, for the third quarter ended September 30, 2024 and $83.4 million, or $1.01 per diluted share, for the fourth quarter ended December 31, 2023. Adjusted net income for the quarter was $86.1 million, or $1.07 per diluted share, which compares to $92.8 million, or $1.15 per diluted share, for the third quarter ended September 30, 2024 and $83.4 million, or $1.01 per diluted share, for the fourth quarter ended December 31, 2023.
Neutral
GlobeNewsWire
2 months ago
NMI Holdings, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on February 6, 2025
EMERYVILLE, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- NMI Holdings, Inc. (NASDAQ: NMIH), the parent company of National Mortgage Insurance Corporation (National MI), today announced that it will report results for its fourth quarter and full year ended December 31, 2024 after the market close on Thursday, February 6, 2025.
Positive
Zacks Investment Research
2 months ago
NMI Holdings Stock Trades Above 50-Day SMA: What Should Investors Do?
NMIH stock is poised to gain from higher new insurance written volume, a comprehensive reinsurance program, financial flexibility and prudent capital deployment.
Positive
Seeking Alpha
2 months ago
Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI +
The 'Undercovered' Dozen series highlights lesser-covered stocks, providing investment ideas and encouraging discussions on their potential. Arcus Biosciences is seen as a "Strong Buy" due to its promising oncology combo therapies and partnerships with Gilead and AstraZeneca. Edmund Ingham sees Sarepta Therapeutics, despite past valuation concerns, as a "Buy" with potential for >50% gain by YE25, driven by Elevidys and ongoing clinical programs.
Charts implemented using Lightweight Charts™